Exosens shares lead the SBF 120 after a Bernstein target price increase

Bernstein raises its target to €74 and confirms its positive opinion on the stock

Bernstein raised its price target on Exosens on Wednesday, moving from €71.50 to €74, while maintaining its outperform rating. The new target represents an upside potential of approximately 17% compared to the current price of €63.05. Invest Securities had already followed suit last Tuesday, raising its target from €67 to €70, with a buy recommendation maintained.

The consensus of analysts therefore converges towards targets substantially above current prices, demonstrating positive conviction on the group's trajectory. This upward movement in targets follows the revision of annual targets published on September 17, which projected approximately 20% revenue growth and approximately 25% adjusted EBITDA growth in 2026, with targeted revenue of up to 570 million euros.

Leading the SBF 120, the stock consolidates its technical advance with gains of 16% over the week

With an intraday gain of 3.62% at €63.05, Exosens posts the best performance on the SBF 120 at mid-morning, in an index that barely advances 0.05%. Over the week, the stock shows nearly 16.5% appreciation, reflecting the sequence triggered by the publication of new annual targets. The price is trading well above its three moving averages: 9.3% above the 20-day MA at €57.69 and approximately 6.6% above the 200-day MA at €59.17, confirming a sharp recovery after the weeks of pressure observed in early September.

The RSI at 58 remains in neutral territory, with no overbought signal despite the amplitude of the weekly rebound. The next identified resistance is at €66.80, approximately 5.9% above the current price.